2025/07/07 by Frontiers Editorial Office · 1 voice
Economics, Econometrics and Finance · Medicine · #Biology #COVID-19 Pandemic Impacts #Coronavirus #Coronavirus disease 2019 (COVID-19) #Disease #Genetics #Globalization #Infectious disease (medical specialty) #Medicine #Pandemic #Political science #Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) #Virology #Zoonosis
paper · pdf · doi:10.3389/fmicb.2025.1656738
openalex publication_date 2025/07/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
An Expression of Concern onAnalysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics,By Colson P, Fournier P-E, Chaudet H, Delerce J, Giraud-Gatineau A, Houhamdi L, Andrieu C, Brechard L, Bedotto M, Prudent E, Gazin C, Beye M, Burel E, Dudouet P, Tissot-Dupont H, Gautret P, Lagier J-C, Million M, Brouqui P, Parola P, Fenollar F, Drancourt M, La Scola B, Levasseur A and Raoult D (2022) Analysis of SARSCoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics. Front. Microbiol. 12:786233. doi: 10.3389/fmicb.2021.786233Following publication, it was brought to our attention that the ethical approval for this study referred to the same ethics approval number 2020-016-03 that had been used across a series of unrelated published studies (1–10). Additionally, an issue around the potential need for approval from a Comité de Protection de Personnes was raised and remains unresolved.An investigation conducted by the Comité d'éthique at Aix-Marseille Université confirmed that this study is retrospective and did not require approval from a Comité de Protection de Personnes. The institution stated that the quoted ethics approval 2020-016-03 is a generic opinion concerning the study of genetic diversity and evolution of SARS-COV-2 which is valid for any study on this topic.Frontiers has not received the necessary documentation to confirm these statements.1. Dao TL, Hoang VT, Nguyen NN, Delerce J, Chaudet H, Levasseur A, et al. Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France. Clin Microbiol Infect. 2021 Oct 1;27(10):1516.e1-1516.e6. 2. Hoang VT, Colson P, Levasseur A, Delerce J, Lagier JC, Parola P, et al. Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. Infect Genet Evol. 2021 Nov 1;95:105092. 3. Gautret P, Houhamdi L, Nguyen NN, Hoang VT, Giraud-Gatineau A, Raoult D. Does SARS-CoV-2 reinfection depend on virus variant? Clin Microbiol Infect. 2021 Sep 1;27(9):1374–5. 4. Hoang VT, Assoumani L, Delerce J, Houhamdi L, Bedotto M, Lagier JC, et al. Introduction of the SARS-CoV2 Beta variant from Comoros into the Marseille geographical area. Travel Med Infect Dis. 2022 Mar 1;46:102277. 5. Colson P, Fantini J, Yahi N, Delerce J, Levasseur A, Fournier PE, et al. Limited spread of a rare spike E484Kharboring SARS-CoV-2 in Marseille, France. Arch Virol. 2022 Feb 1;167(2):583–9. 6. Colson P, Delerce J, Burel E, Beye M, Fournier PE, Levasseur A, et al. Occurrence of a substitution or deletion of SARS-CoV-2 spike amino acid 677 in various lineages in Marseille, France. Virus Genes. 2022 Feb 1;58(1):53–8. 7. Colson P, Delerce J, Pontarotti P, Devaux C, La Scola B, Fantini J, et al. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction. J Med Virol. 2024;96(2):e29462. 8. Colson P, Chaudet H, Delerce J, Pontarotti P, Levasseur A, Fantini J, et al. Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic. J Infect. 2024 May 1;88(5):106150. 9. La Scola B, Lavrard P, Fournier PE, Colson P, Lacoste A, Raoult D. SARS-CoV-2 variant from India to Marseille: The still active role of ports in the introduction of epidemics. Travel Med Infect Dis. 2021 Jul 1;42:102085. 10. Colson P, Levasseur A, Delerce J, Pinault L, Dudouet P, Devaux C, et al. Spreading of a new SARS